SEATTLE, Aug. 17 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced publication of results from a Phase 1 study of NEUVENGE, an investigational active cellular immunotherapy, in the August 20 issue of the Journal of Clinical Oncology. The article highlights the safety profile, immune response and clinical activity of NEUVENGE in women with HER2/neu-positive breast cancer who have failed standard therapy.
"In addition to demonstrating that NEUVENGE was safe and well tolerated, the T-cell responses seen in these patients and the prolonged disease stabilization in the absence of other anti-cancer therapies in many patients is promising," said John W. Park, M.D., associate clinical professor of medicine and neurosurgery at the University of California, San Francisco and lead author of the publication. "These observations are encouraging and are suggestive of the clinical benefit of NEUVENGE, particularly in light of the aggressive cancer seen in these patients who had progressed while on standard therapy. The findings warrant additional studies of NEUVENGE for the many women with advanced breast cancer who have exhausted many of their treatment options."
The Phase 1 study (D2000-2) was conducted to evaluate the safety and
immunologic activity of NEUVENGE in patients with HER2-overexpressing
metastatic breast cancer who had failed standard therapy, including prior
treatment with chemotherapy and trastuzumab. All patients had experienced
disease progression while on standard therapy. There were 19 patients
enrolled in the study with 18 patients receiving treatment with NEUVENGE.
Patients underwent three infusions of NEUVENGE at Weeks 0, 2, and 4
|SOURCE Dendreon Corporation|
Copyright©2007 PR Newswire.